



US Analyst Initiation Report on Immuron

3 February 2016, Melbourne, Australia: Immuron Limited (ASX:IMC) wishes to advise investors that US-based equities company SeeThruEquity LLC, has released a research report on the entire Company, its products and Research & Development programs and pipeline.

A copy of the SeeThruEquity's Analyst Report can be viewed on the Immuron Company website at <http://immuron.com/investor-centre/analyst-reports/> or on the US Yahoo Finance website.

SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will also be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Company Contact:

Thomas Liquard
Chief Executive Officer
AUS Ph: +61 (0)3 9824 5254
thomasliquard@immuron.com

Immuron US Investor Relations:

Jon Cunningham
RedChip Companies, Inc.
US Ph: +1 (407) 644 4256, (ext. 107)
jon@redchip.com

About SeeThruEquity LLC:

SeeThruEquity is an equity research and corporate access firm focused on companies with less than \$1 billion in market capitalization. The research is not paid for and is unbiased. They do not conduct any investment banking or commission based business. They are approved to contribute our research to Thomson Reuters One (First Call), CapitalIQ, FactSet, and Zacks and distribute their research to our database of opt-in investors. They also contribute their estimates to Thomson Estimates, the leading estimates platform on Wall Street.

SeeThruEquity started in March 2011 and since then, they have initiated coverage on numerous NYSE, NASDAQ, TSX, and OTC companies in a variety of industries including technology, health care, consumer, energy and special situations and have hosted several investor conferences in New York City.

For more information visit: <http://www.seethruequity.com>

About Immuron:

Immuron Ltd (ASX: IMC; OTCQB: IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers' diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company's other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

For more information visit: <http://www.immuron.com/>

Forward-Looking Statements:

Certain statements made in this release are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.